The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Efficacy of Ecabet Sodium for Helicobacter pylori Eradication, Combined with Lansoprazole-Based Triple Regimen: A Prospective Study

Lansoprazole 근간 3제요법과 병합 투여된 Ecabet Sodium이 Helicobacter pylori 제균율에 미치는 효과

  • Seo, Jung-Yeon (Department of Internal Medicine, Hanil General Hospital) ;
  • Kim, Min-Jeong (Department of Internal Medicine, Hanil General Hospital) ;
  • Ko, Kyu-Han (Department of Internal Medicine, Hanil General Hospital) ;
  • Kim, Dong-Hyun (Department of Internal Medicine, Hanil General Hospital) ;
  • Lim, Dae-Seop (Department of Internal Medicine, Hanil General Hospital) ;
  • Chon, Hae-Ri (Department of Internal Medicine, Hanil General Hospital)
  • Published : 2011.05.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Ecabet sodium is used for treating gastric ulcers and gastritis. It exhibits a bactericidal effect againstHelicobacter pylori by inhibiting bacterial urease activity. Thus, ecabet sodium has been suggested to improve the efficacy of theH. pylori eradication in patients with peptic ulcers. The aim of this study was to compare the H. pylori eradication rate oflansoprazole-based triple therapy versus lansoprazole-based triple therapy plus ecabet sodium.Methods: The subjects consisted of 363 H. pylori-positive patients who had undergone eradication therapy from February 2007 toFebruary 2010. In total, 363 patients with H. pylori-positive peptic ulcer disease or symptomatic erosive gastritis received LAC(lansprazole 30 mg b.i.d., amoxicillin 1.0 g b.i.d., clarithromycin 500 mg b.i.d.) or LACE (lansoprazole 30 mg b.i.d., amoxicillin1.0 g b.i.d., clarithromycin 500 mg b.i.d., ecabet sodium 1 g b.i.d.) for 1 week. Successful eradication was defined as a negative13Curea breath test 4-5 weeks after treatment completion.Results: H. pylori eradication rates were 81.4% (166/204) in the LAC group and 86.2% (137/159) in the LACE group (p = 0.159).No significant difference in eradication was observed. No significant difference was observed in the side effects experienced by thepatients in the two treatment groups.Conclusions: Our results suggest that adding ecabet sodium did not improve the H. pylori eradication rate significantly in standardlansoprazole-based triple therapy for H. pylori.

목적: 위세포벽을 보호하는 효과로 소화성 궤양환자에 사용되는 ecabet sodium은 H. pylori 요소분해효소를 억제함으로써 H. pylori의 활동과 성장을 억제시키는 약물로 알려져있다. 이에 기존의 LAC 삼제요법과 ecabet sodium을 병합한 LAC 삼제요법(lansoprazole + amoxicillin + clarithromycin)을 사용한 환자들 간의 H. pylori 제균율의 차이를 비교하여 ecabet sodium이 H. pylori 제균율에 미치는 효과를 평가하고자 하였다. 방법: 상부위장관 내시경으로 H. pylori 양성 소화성 궤양 또는 미란성 위염으로 진단받고 LAC (lansoprazole 30 mg b.i.d., amoxacillin 1.0 g b.i.d., clarithromycin 500 mg b.i.d.) 또는 LACE (lansoprazole 30 mg b.i.d., amoxacillin 1.0 g b.i.d., clarithromycin 500 mg b.i.d., ecabet sodium 1 g b.i.d.)로 2주간 H. pylori 제균 치료를 받았던 두 군을 투약종료 4-5주 후에 $^{13}C$요소호기검사를 실시하여 두 군 간 H. pylori 제균율을 비교하였다. 결과: 대상 환자는 LAC군 204명, LACE군 159명으로 총363명이었고, 양 군 간의 흡연력, 나이, 성별 및 진단명에는 유의한 차이는 없었다. H. pylori 제균율에 있어서 LAC군은 81.4%, LACE군은 86.2%로 ecabet sodium을 사용한 군에서 사용하지 않은 군과 비교 시 제균율에 차이가 없었다(p = 0.159). 결론: H. pylori의 제균 요법으로 ecabet sodium을 병합 투여한 3제 요법은 기존의 3제 요법과 제균율에 있어서 차이가 없었다.

Keywords

References

  1. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1:1273-1275.
  2. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer: a randomized, controlled study. Ann Intern Med 1992;116:705-708. https://doi.org/10.7326/0003-4819-116-9-705
  3. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosaassociated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-577. https://doi.org/10.1016/0140-6736(93)91409-F
  4. Hirayama F, Takagi S, Iwao E, Yokoyama Y, Haga K, Hanada S. Development of poorly differentiated adenocarcinoma and carcinoid due to long-term Helicobacter pylori colonization in Mongolian gerbils. J Gastroenterol 1999;34:450-454. https://doi.org/10.1007/s005350050295
  5. Honda S, Fujioka T, Tokieda M, Satoh R, Nishizono A, Nasu M. Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils. Cancer Res 1998;58:4255-4259.
  6. 대한 Helicobacter pylori 연구회. 한국인에서의 Helicobacter pylori 감염의 진단 및 치료. 대한소화기학회지 1998;32:275-289.
  7. 정인식. Helicobacter pylori 감염의 진단 및 한국의 치료지침. 대한내과학회지 1998;55:724-737.
  8. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002;16: 167-180.
  9. Satoh K. Indications for Helicobacter pylori eradication therapy and first-line therapy regimen in Japan: recommendation by the Japanese Society for Helicobacter Research. J Gastroenterol 2002;37(Suppl 13):S34-S38.
  10. Yoo HM, Lee YC, Park HJ, Kim WH, Lee KW, Park IS. Clinical characteristics of patients with failed eradication of Helicobacter pylori and antibiotic resistance. Korean J Gastroenterol 1999; 33:311-320.
  11. Ito Y, Nakamura S, Onoda Y, Sugawara Y, Takaiti O. Effects of the new anti-ulcer drug ecabet sodium (TA-2711) on pepsin activity: I. inactivation of enzyme protein. Jpn J Pharmacol 1993;62: 169-174. https://doi.org/10.1254/jjp.62.169
  12. Shimoyama T, Fukuda Y, Fukuda S, Munakata A, Yoshida Y, Shimoyama T. Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients. J Gastroenterol 1996;31(Suppl 9):S59-S62.
  13. Onoda Y, Magaribuchi T, Tamaki H. Effects of 12-sulfodehydroabietic acid monosodium salt (TA-2711), a new anti-ulcer agent, on gastric secretion and experimental ulcers in rats. Jpn J Pharmacol 1989;51:65-73. https://doi.org/10.1254/jjp.51.65
  14. Onoda Y, Takido M, Magaribuchi T, Tamaki H. Effects of 12-sulfodehydroabietic acid monosodium salt (TA-2711), a new anti-ulcer agent, on gastric mucosal lesions induced by necrotizing agents and gastric mucosal defensive factors in rats. Jpn J Pharmacol 1990;52:631-638. https://doi.org/10.1254/jjp.52.631
  15. Onoda Y, Iwasaki H, Magaribuchi T, Tamaki H. Effects of the new anti-ulcer agent 12-sulfodehydroabietic acid monosodium salt on healing of acetic acid-induced gastric ulcers in rats. Arzneimittelforschung 1991;41:546-548.
  16. Kinoshita M, Tamaki H. Possible mechanism of increase in gastric mucosal PGE2 and PGI2 generation induced by ecabet sodium, a novel gastroprotective agent. Dig Dis Sci 1997;42:83-90. https://doi.org/10.1023/A:1018885005109
  17. Kinoshita M, Endo M, Yasoshima A, et al. Ecabet sodium, a novel locally-acting anti-ulcer agent, protects the integrity of the gastric mucosal gel layer from pepsin-induced disruption in the rat. Aliment Pharmacol Ther 1999;13:687-694. https://doi.org/10.1046/j.1365-2036.1999.00502.x
  18. 김정목, 김주성, 정현채 등. Ecabet sodium이 Helicobacter pylori에 감염된 인체 위상피세포에서의 핵전사인자 활성과 chemokine 유전자 발현에 미치는 영향. 대한내과학회지 2003;65:178-187.
  19. Shimoyama T, Fukuda S, Liu Q, Nakaji S, Munakata A, Sugawara K. Ecabet sodium inhibits the ability of Helicobacter pylori to induce neutrophil production of reactive oxygen species and interleukin-8. J Gastroenterol 2001;36:153-157. https://doi.org/10.1007/s005350170122
  20. Shibata K, Kasuga O, Yasoshima A, Matsushita T, Kawakami Y. Bactericidal effect of ecabet sodium on clarithromycin- and metronidazole-resistant clinical isolates of Helicobacter pylori. Jpn J Antibiot 1997;50:525-531.
  21. Ito Y, Hongo A, Kinoshita M, Tamaki H. Mechanism of anti-urease action by the anti-ulcer drug ecabet sodium. Biol Pharm Bull 1995;18:850-853. https://doi.org/10.1248/bpb.18.850
  22. Ito Y, Shibata K, Hongo A, Kinoshita M. Ecabet sodium, a locally acting antiulcer drug, inhibits urease activity of Helicobacter pylori. Eur J Pharmacol 1998;345:193-198. https://doi.org/10.1016/S0014-2999(97)01622-1
  23. Fukuda Y, Yamamoto I, Okui M, Tonokatsu Y, Shimoyama T. Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients. J Clin Gastroenterol 1995;20(Suppl 2):S132-S135.
  24. Shimoyama T, Fukuda Y, Fukuda S, Munakata A, Yoshida Y, Shimoyama T. Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients. J Gastroenterol 1996;31(Suppl 9):S59-S62.
  25. Ohkusa T, Takashimizu I, Fujiki K, et al. Prospective evaluation of a new anti-ulcer agent, ecabet sodium, for the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1998; 12:457-461. https://doi.org/10.1046/j.1365-2036.1998.00324.x
  26. Kagaya H, Kato M, Komatsu Y, et al. High-dose ecabet sodium improves the eradication rate of Helicobacter pylori in dual therapy with lansoprazole and amoxicillin. Aliment Pharmacol Ther 2000;14:1523-1527. https://doi.org/10.1046/j.1365-2036.2000.00852.x
  27. Fuccio L, Minardi ME, Zagari RM, Grilli DM, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-562. https://doi.org/10.7326/0003-4819-147-8-200710160-00008